Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. The company serves the pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Ginkgo Bioworks Holdings Inc. Class A

An announcement from DeNA Co ( ($JP:2432) ) is now available. DeNA has overhauled its dividend policy to prioritize stable shareholder returns tied...

DeNA Shifts to DOE-Based Dividend Policy and Hikes FY2026 Payout Forecast

DeNA Co ( ($JP:2432) ) has provided an update. DeNA has revised its consolidated earnings forecast for the fiscal year ending March 31, 2026, lower...

DeNA Cuts Profit Outlook on Goodwill Impairment Despite Solid Core Businesses

An announcement from DeNA Co ( ($JP:2432) ) is now available. DeNA reported consolidated revenue of ¥114.5 billion for the nine months ended Decemb...

DeNA Lifts Dividend Outlook Despite Lower Revenue and Profit Forecasts

In a report released today, Vishal Shreedhar from National Bank maintained a Hold rating on Canadian Tire, with a price target of C$201.00. Accordi...

National Bank Keeps Their Hold Rating on Canadian Tire (CDNAF)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ufp Technologies (UFPT – Research Report), Eledon ...

Analysts Conflicted on These Healthcare Names: Ufp Technologies (UFPT), Eledon Pharmaceuticals (ELDN) and CareDx (CDNA)

Medicenna Therapeutics Corp ( ($TSE:MDNA) ) has shared an announcement. Medicenna reported updated clinical data for its lead IL-2 super agonist MD...

Medicenna Maps 2026 Milestones as IL-2 Superkine MDNA11 Delivers Promising Cancer Responses

Medicenna Therapeutics Corp ( ($TSE:MDNA) ) just unveiled an announcement. Medicenna Therapeutics outlined a potentially pivotal 2026 as it advance...

Medicenna Targets Pivotal 2026 as IL-2 Superkine Programs Advance Toward Registrational Trials

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Axsome Therapeutics (AXSM – Research Report), Vert...

Market Cap	$532.59M	P/E Ratio	N/A
52W High	$17.58	52W Low	$5.00
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	42.0%	52W Position	40.5%
Overall Score	51	Value Score	60
Quality Score	44	Technical Score	50

EPS Current Est	$-5.94	EPS Next Est	$-4.33
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DNA	$10.10	+21.39%	2.65M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DNA	$10.10	+21.4%	2.65M
3
4
5
6

DNA

DNA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Ginkgo Bioworks Holdings Inc. Class A Data in Excel

Get Ginkgo Bioworks Holdings Inc. Class A Data in Excel